Want to see KYMR full AI Analyst Report?
KYMR Stock Chart & Stats
$110.57
-$0.08(-0.07%)
At close: 4:00 PM EDT
$110.57
-$0.08(-0.07%)
Day’s Range― - ―
52-Week Range$36.65 - $130.05
Previous CloseN/A
Volume157.52K
Average Volume (3M)1.05M
Market Cap
$8.80B
Enterprise Value$7.55K
Total Cash (Recent Filing)$650.93M
Total Debt (Recent Filing)$80.47M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Aug 05, 2026EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.58
Shares Outstanding82,257,590
10 Day Avg. Volume575,796
30 Day Avg. Volume1,051,347
Financial Highlights & Ratios
PEG Ratio-0.89
Price to Book (P/B)4.16
Price to Sales (P/S)167.51
P/FCF Ratio-28.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$130.07Price Target Upside17.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)-3.47
Revenue Forecast (FY)$85.42M
Bulls Say, Bears Say
Bulls Say
Targeted Protein Degradation PlatformKymera’s proprietary small-molecule targeted protein degradation platform is a durable strategic asset: it addresses disease-causing proteins inaccessible to traditional modalities, enables multiple distinct programs across immunology and oncology, and supports long-term pipeline generation and partner interest independent of short-term market moves.
Accelerated KT-621 DevelopmentFaster-than-expected enrollment and Fast Track status for KT-621 materially shorten clinical timelines and de-risk the program structurally: earlier topline readout improves the company’s ability to make program decisions, pursue Phase 3 initiation by mid-2027, and strengthen partnering or financing options over the next 2–6 months and beyond.
Low Leverage And Sizable Equity BaseA very low debt load and a large equity base give Kymera durable financial flexibility typical for development-stage biotech: management can fund R&D via equity or partnerships without heavy fixed obligations, lowering near-term default risk and preserving optionality to advance multiple programs.
Bears Say
High Cash BurnSustained quarterly cash outflows at this magnitude create a structural funding requirement: absent near-term commercialization, Kymera must secure partner payments or raise capital, which increases dilution risk and can constrain investment choices across programs over the medium term.
Large And Widening Net LossesVery large, growing operating losses and negative margins reflect ongoing R&D intensity without current revenue offset, weakening return metrics and pressuring equity over time. This persistent unprofitability raises execution risk and dependence on external funding to sustain pipeline progression.
Dependence On Partnerships And FinancingsAs a clinical-stage firm with little to no commercial revenue, Kymera’s ability to advance programs depends on milestone-based partner payments and periodic equity raises. That structural funding model creates revenue timing uncertainty and dilution risk, especially if clinical progress or deal markets slow.
Kymera Therapeutics News
KYMR FAQ
What was Kymera Therapeutics, Inc.’s price range in the past 12 months?
Kymera Therapeutics, Inc. lowest stock price was $36.65 and its highest was $130.05 in the past 12 months.
What is Kymera Therapeutics, Inc.’s market cap?
Kymera Therapeutics, Inc.’s market cap is $8.80B.
When is Kymera Therapeutics, Inc.’s upcoming earnings report date?
Kymera Therapeutics, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 4 days.
How were Kymera Therapeutics, Inc.’s earnings last quarter?
Kymera Therapeutics, Inc. released its earnings results on Apr 30, 2026. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.881 by $0.171.
Is Kymera Therapeutics, Inc. overvalued?
According to Wall Street analysts Kymera Therapeutics, Inc.’s price is currently Undervalued.
Does Kymera Therapeutics, Inc. pay dividends?
Kymera Therapeutics, Inc. does not currently pay dividends.
What is Kymera Therapeutics, Inc.’s EPS estimate?
Kymera Therapeutics, Inc.’s EPS estimate is -0.71.
How many shares outstanding does Kymera Therapeutics, Inc. have?
Kymera Therapeutics, Inc. has 82,257,590 shares outstanding.
What happened to Kymera Therapeutics, Inc.’s price movement after its last earnings report?
Kymera Therapeutics, Inc. reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.881. Following the earnings report the stock price went down -0.54%.
Which hedge fund is a major shareholder of Kymera Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kymera Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$130.07 (17.63% Upside)
$130.07 (17.63% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 104.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $174.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
141.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
81.75%
Trailing 12-Months
Company Description
Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
KYMR Company Deck
KYMR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical momentum (notably KT-621 and KT-579), significant balance sheet strength (raised ~ $1B; $1.6B year-end cash) and multiple high-value collaborations, all supporting an ambitious development plan. Headwinds include elevated R&D spend (adjusted cash R&D +16% QoQ), limited current revenue, translational/measurement complexity for IRF5, and multi-year timelines to pivotal readouts and potential approvals. Overall, the positives—compelling early clinical data, IND/Phase I starts, partner validation and a multi-year cash runway—outweigh the noted operational and timing risks.View all KYMR earnings summariesKYMR Stock 12 Month Forecast
Average Price Target
$130.07
▲(17.63% Upside)
Technical Analysis
Protagonist Therapeutics
―
―
Crinetics Pharmaceuticals
―
―
MoonLake Immunotherapeutics
―
Ownership Overview
12.10% Insiders
36.88% Mutual Funds
0.23% Other Institutional Investors
36.24% Public Companies and
Individual Investors